Literature DB >> 11253134

Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed.

D J Waghorn1.   

Abstract

AIMS: Patients without spleens are at increased risk of overwhelming infection. Recently, greater efforts, including the publication of national guidelines, have been made to improve the management of asplenic individuals. In theory, risks of serious sepsis can be reduced by good advice, immunisation, and antibiotic prophylaxis. In practice, such preventive measures might not be followed or may fail. A study of recent cases of overwhelming postsplenectomy infection (OPSI) was undertaken to examine specific associated factors and to determine whether currently recommended preventive measures are being followed.
METHODS: Cases of OPSI were identified and reported mainly by microbiologists across the country using a specifically designed proforma. Data including the nature of the infection and vaccination/ antibiotic prophylaxis history since splenectomy were obtained.
RESULTS: Seventy seven cases were reported. The age range varied from 3 months (congenital asplenia) to 87 years. In those who had undergone surgical splenectomy, the time interval between surgery and OPSI varied from 24 days to 65 years. Overall mortality reached 50%, with underlying haematological malignancy associated with the highest death rate. Streptococcus pneumoniae caused approximately 90% episodes. Only 31% individuals had received pneumococcal vaccination before OPSI. Seven of 17 pneumococcal infections in immunised cases could be considered vaccine failures. Few patients had been adequately advised on antibiotic prophylaxis or other measures.
CONCLUSIONS: Currently accepted best practice for managing asplenic patients is not being followed. Some OPSI cases may still be preventable but many asplenic individuals remain unrecognised. The compilation of asplenic patient registers might help to implement agreed policies with audit necessary to evaluate compliance. More is needed to ensure optimal management for this cohort of the population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253134      PMCID: PMC1731383          DOI: 10.1136/jcp.54.3.214

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  24 in total

1.  The spleen? Who needs it anyway?

Authors:  M Hazlewood; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 2.  Modern vaccines. Pneumococcus and influenza.

Authors:  F Shann
Journal:  Lancet       Date:  1990-04-14       Impact factor: 79.321

3.  Managing patients with an absent or dysfunctional spleen. Uncertainty exists over frequency of blood tests to test antipneumococcal immunity.

Authors:  G C Kassianos
Journal:  BMJ       Date:  1996-05-25

4.  Avoiding infection after splenectomy.

Authors:  D J Waghorn; E Haworth
Journal:  Br J Gen Pract       Date:  1996-11       Impact factor: 5.386

5.  Pneumococcal infections in splenectomized children are preventable.

Authors:  H B Konradsen; J Henrichsen
Journal:  Acta Paediatr Scand       Date:  1991-04

6.  Prevention of postsplenectomy sepsis.

Authors:  D J Waghorn
Journal:  Lancet       Date:  1993-01-23       Impact factor: 79.321

7.  Prevention of post splenectomy sepsis: a population based approach.

Authors:  J Sarangi; M Coleby; M Trivella; S Reilly
Journal:  J Public Health Med       Date:  1997-06

8.  Pneumococcal vaccine administration associated with splenectomy: missed opportunities.

Authors:  E A Kind; C Craft; J B Fowles; C E McCoy
Journal:  Am J Infect Control       Date:  1998-08       Impact factor: 2.918

Review 9.  Prophylaxis against late infection following splenectomy and bone marrow transplant.

Authors:  A K Fielding
Journal:  Blood Rev       Date:  1994-09       Impact factor: 8.250

10.  Postsplenectomy sepsis and mortality in adults.

Authors:  P E Schwartz; S Sterioff; P Mucha; L J Melton; K P Offord
Journal:  JAMA       Date:  1982-11-12       Impact factor: 56.272

View more
  75 in total

1.  Antibiotics for Travelers: What's Good and What's Not.

Authors:  Kathryn N. Suh; Jay S. Keystone
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 2.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

3.  Prevention of infection post-splenectomy: time for implementation of guidelines.

Authors:  B O'Connell
Journal:  Ir J Med Sci       Date:  2004 Jul-Sep       Impact factor: 1.568

Review 4.  Minimally invasive splenectomy: an update and review.

Authors:  Gary Gamme; Daniel W Birch; Shahzeer Karmali
Journal:  Can J Surg       Date:  2013-08       Impact factor: 2.089

5.  Management of post-splenectomy patients in the Netherlands.

Authors:  A J J Lammers; D Veninga; M J M H Lombarts; J B L Hoekstra; P Speelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-22       Impact factor: 3.267

6.  Murine spleen tissue regeneration from neonatal spleen capsule requires lymphotoxin priming of stromal cells.

Authors:  Jonathan K H Tan; Takeshi Watanabe
Journal:  J Immunol       Date:  2014-06-20       Impact factor: 5.422

7.  Partial spleen resection with a radiofrequency needle device--a pilot study.

Authors:  Juliane Liese; Sven Kohler; Christian Moench; Wolf Otto Bechstein; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-02-06       Impact factor: 3.445

Review 8.  Laparoscopic Splenectomy for Benign Hematological Disorders in Adults: A Systematic Review.

Authors:  Demetrios Moris; Nikoletta Dimitriou; John Griniatsos
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 9.  Cardiac and Non-Cardiac Abnormalities in Heterotaxy Syndrome.

Authors:  Smita Mishra
Journal:  Indian J Pediatr       Date:  2015-11-26       Impact factor: 1.967

10.  [Distal pancreatectomy: radical or spleen-preserving?].

Authors:  A M Chromik; M Janot; D Sülberg; M H Seelig; W Uhl
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.